Denali Therapeutics Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. Properties
Below is a summary of our key leased properties as of December 31, 2025:
California
Our corporate headquarters are located in South San Francisco, California, comprising 148,020 square feet of office, research and development, engineering, and laboratory space pursuant to a lease agreement which commenced on April 12, 2019 and expires on April 30, 2029, with an option to extend for a period of ten years. This facility houses the majority of our personnel.
Utah
Our manufacturing facility is located in Salt Lake City, Utah, comprising approximately 60,000 rentable square feet of office, lab, and clinical manufacturing space pursuant to a lease agreement which commenced on April 1, 2024, and is expected to terminate in 2039. We have two five-year renewal period options to extend the lease for a further ten years at the end of the lease term.
Switzerland
Our European headquarters are located in Zurich, Switzerland, comprising approximately 163 square meters (approximately 1,755 square feet) of office space pursuant to a lease agreement that commenced on November 1, 2025 and expires on October 31, 2030, with an option to extend the lease for an additional five-year period. This facility is used for office and administrative purposes.
We believe that our existing premises are adequate for our current needs.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.